Physician profile
Nicole D Eustace
NPI 1346505278
$2,552.37
in general payments reported to CMS, 2019-2025
27 companies · $803 in 2025
The $803 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $28.76 · 2021: $281 · 2022: $305 · 2023: $342 · 2024: $793 · 2025: $803.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,937.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $694.98 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $511.92 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $257.59 | 2023-2025 | Caplyta |
| Pfizer INC. | $247.01 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $98.32 | 2021-2024 | Farxiga |
| Astellas Pharma US INC | $85.77 | 2023-2024 | Veozah |
| Axsome Therapeutics, INC. | $68.86 | 2025 | Auvelity |
| Novo Nordisk INC | $64.83 | 2020-2024 | Rybelsus, Ozempic, Wegovy |
| Lundbeck LLC | $63.57 | 2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $48.46 | 2022 | |
| Lilly USA, LLC | $46.38 | 2022-2023 | Mounjaro |
| Teva Pharmaceuticals USA, INC. | $40.61 | 2025 | Austedo Xr |
| Corium, LLC | $36.98 | 2025 | Azstarys |
| Idorsia Pharmaceuticals US INC | $34.34 | 2023-2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $31.54 | 2023-2024 | Jornay Pm |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $30.27 | 2024 | Evenity, Prolia |
| Takeda Pharmaceuticals U.S.A., INC. | $30.18 | 2024 | Trintellix |
| Vertex Pharmaceuticals Incorporated | $23.37 | 2025 | |
| Impel Pharmaceuticals INC. | $21.52 | 2023 | Trudhesa |
| Sumitomo Pharma America, INC. | $19.57 | 2025 | Gemtesa |
| Collegium Pharmaceutical, INC. | $18.38 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $16.65 | 2025 | |
| Exact Sciences Corporation | $15.43 | 2023 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $14.30 | 2024 | Eliquis |
| Tris Pharma INC | $13.14 | 2024 | |
| Allergan, INC. | $11.98 | 2020 | |
| Organon LLC | $6.42 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Eustace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.